Literature DB >> 1528603

Immunologic abnormality in Menière's disease.

M Suzuki1, M Kitahara.   

Abstract

Patients with Meniere's disease were investigated for possible immunologic abnormalities. A total of 104 cases--55 bilateral and 49 unilateral--were examined. Immune activity was assessed using four types of immune parameters: (1) the erythrocyte sedimentation rate (ESR) and C-reactive protein levels (CRP); (2) serum immunoglobulin levels (IgG, IgM, and IgA); (3) complement levels (C3, C4, and CH50); and (4) autoantibody levels (rheumatoid factor, anti-DNA antibody, and antinuclear antibody). Patients with severe immunologic abnormalities (16% of the bilateral cases and 2% of the unilateral cases) typically displayed bilateral severe hearing loss, bilateral decreased vestibular response, and excellent responsiveness to steroid treatment. As patients with bilateral involvement account for approximately 30% of all cases of Meniere's disease in Japan, immunologic involvement may be assumed in about 6% of the total. The severity of these patients' symptoms and their responsiveness to steroid treatment suggest that the possibility of immunologic involvement is well worth investigation in Meniere's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528603     DOI: 10.1177/019459989210700109

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

1.  Incidence of Hypothyroidism in Meniere's Disease.

Authors:  U P Santosh; M S Sudhakar Rao
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Non-specific immunological determinations in Meniere's disease: any role in clinical practice?

Authors:  Marina Savastano; Luciano Giacomelli; Gino Marioni
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-11       Impact factor: 2.503

3.  Association between Ménière's disease and thyroid diseases: a nested case-control study.

Authors:  So Young Kim; Young Shin Song; Jee Hye Wee; Chanyang Min; Dae Myoung Yoo; Hyo Geun Choi
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.